Texas 2019 86th Regular

Texas House Bill HB1866 Introduced / Bill

Filed 02/15/2019

                    86R6949 JSC-F
 By: Davis of Dallas H.B. No. 1866


 A BILL TO BE ENTITLED
 AN ACT
 relating to the prescribing of opioids for acute pain.
 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
 SECTION 1.  Subchapter C, Chapter 481, Health and Safety
 Code, is amended by adding Section 481.07635 to read as follows:
 Sec. 481.07635.  PRESCRIPTIONS OF OPIOIDS FOR ACUTE PAIN.
 (a) In this section, "acute pain" means pain with abrupt onset that
 is caused by an injury or other process that is not ongoing.
 (b)  For the initial treatment of acute pain, a prescriber
 may not issue a prescription for an opioid in an amount that exceeds
 a seven-day supply.
 (c)  Before issuing an initial opioid prescription for acute
 pain, a prescriber shall:
 (1)  take and document the results of a thorough
 medical history, including:
 (A)  the patient's experience with medication
 other than opioids and pain management approaches described by
 Subsection (d); and
 (B)  any history of substance abuse;
 (2)  conduct and document the results of a physical
 examination, as appropriate;
 (3)  develop a treatment plan focused on determining
 the cause of the patient's pain; and
 (4)  comply with the requirements of Section 481.0764.
 (d)  A prescriber may refer or prescribe any of the following
 pain management services to a patient, based on the prescriber's
 clinical judgment and the availability of the treatment, when
 issuing an opioid prescription for acute pain:
 (1)  physical therapies;
 (2)  occupational therapies;
 (3)  chiropractic treatment;
 (4)  physical medicine and rehabilitation; or
 (5)  osteopathic manipulation.
 (e)  This section does not apply to:
 (1)  patients with pain related to:
 (A)  progressive functional neurological deficit;
 (B)  fracture;
 (C)  tumor;
 (D)  infection; or
 (E)  immediate postsurgical recovery;
 (2)  patients with chronic pain that, based on the
 prescriber's clinical judgment, is caused by a disease, illness, or
 injury that would not improve under the therapies and treatments
 described by Subsection (d); or
 (3)  patients receiving:
 (A)  treatment for cancer;
 (B)  emergency or trauma care;
 (C)  hospice care;
 (D)  palliative care;
 (E)  long-term care; or
 (F)  treatment for substance abuse or opioid
 dependence.
 (f)  This section does not require that all of the treatments
 under Subsection (d) be exhausted before the patient may receive a
 prescription for an opioid.
 SECTION 2.  Section 481.003(a), Health and Safety Code, is
 amended to read as follows:
 (a)  The director may adopt rules to administer and enforce
 this chapter, other than Sections 481.073, 481.074, 481.075,
 481.076, 481.0761, 481.0762, 481.0763, 481.07635, 481.0764,
 481.0765, and 481.0766. The board may adopt rules to administer
 Sections 481.073, 481.074, 481.075, 481.076, 481.0761, 481.0762,
 481.0763, 481.07635, 481.0764, 481.0765, and 481.0766.
 SECTION 3.  Section 554.051(a-1), Occupations Code, is
 amended to read as follows:
 (a-1)  The board may adopt rules to administer Sections
 481.073, 481.074, 481.075, 481.076, 481.0761, 481.0762, 481.0763,
 481.07635, 481.0764, 481.0765, and 481.0766, Health and Safety
 Code.
 SECTION 4.  Section 565.003, Occupations Code, is amended to
 read as follows:
 Sec. 565.003.  ADDITIONAL GROUNDS FOR DISCIPLINE REGARDING
 APPLICANT FOR OR HOLDER OF NONRESIDENT PHARMACY LICENSE. Unless
 compliance would violate the pharmacy or drug statutes or rules in
 the state in which the pharmacy is located, the board may discipline
 an applicant for or the holder of a nonresident pharmacy license if
 the board finds that the applicant or license holder has failed to
 comply with:
 (1)  Section 481.073, 481.074, [or] 481.075, 481.076,
 481.0761, 481.0762, 481.0763, 481.07635, 481.0764, 481.0765, or
 481.0766, Health and Safety Code;
 (2)  Texas substitution requirements regarding:
 (A)  the practitioner's directions concerning
 generic substitution;
 (B)  the patient's right to refuse generic
 substitution; or
 (C)  notification to the patient of the patient's
 right to refuse substitution;
 (3)  any board rule relating to providing drug
 information to the patient or the patient's agent in written form or
 by telephone; or
 (4)  any board rule adopted under Section 554.051(a)
 and determined by the board to be applicable under Section
 554.051(b).
 SECTION 5.  Section 481.07635, Health and Safety Code, as
 added by this Act, applies only to a prescription issued on or after
 the effective date of this Act. A prescription issued before the
 effective date of this Act is governed by the law in effect on the
 date the prescription is issued, and the former law is continued in
 effect for that purpose.
 SECTION 6.  This Act takes effect September 1, 2019.